Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Operating Leases (2022 - 2025)

Entrada Therapeutics (TRDA) has 4 years of Operating Leases data on record, last reported at $50.9 million in Q4 2025.

  • For Q4 2025, Operating Leases fell 1.39% year-over-year to $50.9 million; the TTM value through Dec 2025 reached $50.9 million, down 1.39%, while the annual FY2025 figure was $50.9 million, 1.39% down from the prior year.
  • Operating Leases reached $50.9 million in Q4 2025 per TRDA's latest filing, up from $48.0 million in the prior quarter.
  • Across five years, Operating Leases topped out at $69.1 million in Q3 2023 and bottomed at $9.1 million in Q1 2023.
  • Average Operating Leases over 4 years is $44.6 million, with a median of $50.7 million recorded in 2025.
  • Peak YoY movement for Operating Leases: tumbled 61.81% in 2023, then soared 537.26% in 2024.
  • A 4-year view of Operating Leases shows it stood at $17.5 million in 2022, then surged by 244.1% to $60.3 million in 2023, then decreased by 14.38% to $51.6 million in 2024, then decreased by 1.39% to $50.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Leases were $50.9 million in Q4 2025, $48.0 million in Q3 2025, and $49.3 million in Q2 2025.